How many institutions held CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value in Q3 2023?

17 institutional investors reported CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value for Q3 2023. Use the holders table for investor-level position and value details.

Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN)

Q: What does CUSIP 23255M204 represent in this 13F holders report?

CUSIP 23255M204 is the security identifier for CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value used to aggregate holder disclosures.

CUSIP: 23255M204

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class: Equity / Common Stock, no par value
Shares outstanding: 3,367,000
Total 13F shares: 1,072,275
Share change: +76,835
Total reported value: $3,658,805
Price per share: $3.42
Number of holders: 17
Value change: +$244,093
Number of buys: 5
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 23255M204?
CUSIP 23255M204 identifies CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2023
Previous quarter: Q2 2023

Recent filing periods for CUSIP 23255M204:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Slate Path Capital LP	13F	Company	11%	357,880	$1,474,466	—	30 Jun 2023	13F
MFN Partners Management, LP	13F	Company	5%	169,460	$696,481	—	30 Jun 2023	13F
FMR LLC	13F	Company	4.9%	164,949	$677,941	—	30 Jun 2023	13F
Artal Group S.A.	13F	Company	— mixed-class rows	138,955 mixed-class rows	$572,000	—	30 Jun 2023	13F
VANGUARD GROUP INC	13F	Company	2.4%	81,169	$334,416	—	30 Jun 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.88%	29,722	$122,157	—	30 Jun 2023	13F
BlackRock Finance, Inc.	13F	Company	0.53%	18,000	$74,160	—	30 Jun 2023	13F
CAPTRUST FINANCIAL ADVISORS	13F	Company	0.43%	14,631	$60,280	—	30 Jun 2023	13F
JANE STREET GROUP, LLC	13F	Company	0.4%	13,364	$55,060	—	30 Jun 2023	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.16%	5,437	$22,000	—	30 Jun 2023	13F
MORGAN STANLEY	13F	Company	0.02%	823	$3,391	—	30 Jun 2023	13F
ROYAL BANK OF CANADA	13F	Company	0.02%	839	$3,000	—	30 Jun 2023	13F
GROUP ONE TRADING LLC	13F	Company	0.02%	540	$2,219	—	30 Jun 2023	13F
UBS Group AG	13F	Company	0.01%	186	$766	—	30 Jun 2023	13F
RHUMBLINE ADVISERS	13F	Company	0%	22	$94	—	30 Jun 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	14	$58	—	30 Jun 2023	13F
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	13F	Company	0%	1	$4	—	30 Jun 2023	13F
Andreas Busch	3/4/5	Chief Scientific Officer	— class O/S missing	135,000	—	—	20 Jan 2022	3/4/5
Anjeza Gjino	3/4/5	Chief Financial Officer	— class O/S missing	135,000	—	—	20 Jan 2022	3/4/5
Cheryl Gault	3/4/5	Chief Operating Officer	— class O/S missing	135,000	—	—	20 Jan 2022	3/4/5
George H. Conrades	3/4/5	Director	— class O/S missing	20,000	—	—	14 Jun 2022	3/4/5
Marsha Fanucci	3/4/5	Director	— class O/S missing	20,000	—	—	14 Jun 2022	3/4/5
Michael Mendelsohn	3/4/5	Director	— class O/S missing	20,000	—	—	14 Jun 2022	3/4/5
Ole Isacson	3/4/5	Director	— class O/S missing	20,000	—	—	14 Jun 2022	3/4/5
Stephanie Lovell	3/4/5	Director	— class O/S missing	20,000	—	—	14 Jun 2022	3/4/5
Kevin Churchwell	3/4/5	Director	— class O/S missing	10,000	—	—	24 Jun 2021	3/4/5

Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q3 2023

As of 30 Sep 2023, Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,072,275 shares. The largest 10 holders included Slate Path Capital LP, MFN Partners Management, LP, FMR LLC, TYNDALL CAPITAL PARTNERS L P, Artal Group S.A., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., ACADIAN ASSET MANAGEMENT LLC, and Royal Bank of Canada. This page lists 17 institutional shareholders reporting positions in this security for the Q3 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders

Q3 2023 holders

Holder diff

Investor	Q2 2023 Shares	Q3 2023 Shares	Share Diff	Share Chg %	Q2 2023 Value $	Q3 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.